Neurogene
NGNE
74 hedge funds and large institutions have $417M invested in Neurogene in 2020 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 27 increasing their positions, 12 reducing their positions, and 13 closing their positions.
125% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 12
108% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 13
61% more capital invested
Capital invested by funds: $259M → $417M (+$158M)
23% more funds holding
Funds holding: 60 → 74 (+14)
0.3% more ownership
Funds ownership: 2.96% → 3.27% (+0.3%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
31% less call options, than puts
Call options by funds: $387K | Put options by funds: $564K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$20.6M |
| 2 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
+$13.9M |
| 3 |
State Street
Boston,
Massachusetts
|
+$6.43M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$6.09M |
| 5 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
+$3.58M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$10.5M |
| 2 |
Millennium Management
New York
|
-$7.18M |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$4.52M |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$3.41M |
| 5 |
EC
EcoR1 Capital
San Francisco,
California
|
-$2.04M |
NGNE Hedge Fund Activity: Q2 2020 in Review
74 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Neurogene (NGNE) for Q2 2020, worth a combined $417M — up 61% from $259M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new NGNE positions and 13 closed out — a net gain of 14 holders — while 27 added to existing stakes and 12 trimmed.
The largest buyer was BlackRock, adding an estimated $20.6M. The largest seller was OrbiMed, exiting entirely with an estimated $10.5M sold.
- 74 institutional investors held Neurogene (NGNE) as of Q2 2020, up from 60 in Q1 2020.
- Funds reported $417M of Neurogene stock for Q2 2020, up 61% quarter-over-quarter.
- 27 funds opened new Neurogene positions in Q2 2020 and 13 closed out, a net change of +14 holders.
- The largest Neurogene buyer in Q2 2020 was BlackRock, an estimated $20.6M added.
- The largest Neurogene seller in Q2 2020 was OrbiMed, an estimated $10.5M sold.
Based on aggregated 13F filings for Q2 2020.